Grace Xiong

Ms. Grace Xiong

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in JAAD International
Verified
Journal Article
Open access
GXGrace Xiong
Grace Xiong
EYEric Yu
Eric Yu
MHMartin Heung
Martin Heung
JYJaehyeong Yang
Jaehyeong Yang
MLMegan Lowe
Megan Lowe
MAMohannad Abu-Hilal
Mohannad Abu-Hilal
Oral Janus kinase inhibitors (JAKi) are increasingly used in dermatology, rheumatology, gastroenterology, and hematology. While effective, they can cause adverse effects such as acne, nausea, cytopenia, dyslipidemia, and Herpes zoster. Recent reports have linked JAKi usage to weight changes, particularly weight gain, which can significantly impact patients' quality of life. This study aimed to describe the incidence and characteristics of weight changes associated with the use of JAKi. Ovid MEDLINE, Embase, Web of Science, and Clinicaltrials.gov were searched up to April 2024. From 1080 initial articles, 90 studies covering 16,000 patients were selected. Our analysis found a notable incidence of weight gain with JAKi usage. Overall, 5.9% (947/16,000) of patients reported weight again. In randomized control trials, weight gain was observed in 7% (95% CI: 0.04; 0.09) of patients, while weight loss was observed in 1% (95% CI: 0.00; 0.03). Patients with dermatologic indications had lower weight gain rates (4%, 95% CI: 0.01; 0.06) than those with nondermatological indications (7%, 95% CI: 0.04; 0.10). Overall, JAKi therapy is associated with weight changes, particularly weight gain, underscoring the importance of appropriate counseling and weight monitoring. Further long-term studies are needed to better understand the mechanisms and management of JAKi-related weight changes.

4 November 2025 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
GXGrace Xiong
Grace Xiong
DRDaniel G. Rayner
Daniel G. Rayner
LKLauren Kim
Lauren Kim
SMSusheen Mahmood
Susheen Mahmood
TYTiffany Yu
Tiffany Yu
MAMohannad Abu-Hilal
Mohannad Abu-Hilal
Chronic spontaneous urticaria (CSU) is a skin condition that significantly impairs quality of life. While omalizumab remains the standard treatment for patients who have failed antihistamines, emerging therapies show promise in randomized control trials (RCTs). This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU. Four databases were searched for RCTs evaluating omalizumab (75/150/300 mg Q4W), dupilumab (300 mg Q2W), or remibrutinib (25 mg BID) in CSU. Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), Dermatology Life Quality Index (DLQI; DLQI 0/1), disease control (UAS7 ≤ 6), and symptom remission (UAS7 = 0) were assessed at weeks 12/24. Frequentist random-effects network meta-analysis were conducted in R. Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints. Remibrutinib showed the greatest DLQI improvement and second-highest UAS7 reduction and odds of symptom remission. Dupilumab provided sustained itch relief but delayed efficacy. Lower omalizumab doses lacked durability at 24 weeks. Omalizumab 300 mg, followed by remibrutinib, exhibited the highest effect sizes across major outcomes for CSU. Newer therapies such as remibrutinib and dupilumab appear generally effective, offering promising tools for CSU patients who may not respond to standard treatments.

Verified
Journal Article
Open access
PDF file
GXGrace Xiong
Grace Xiong
MSMuskaan Sachdeva
Muskaan Sachdeva
Gil YosipovitchGil Yosipovitch
Gil Yosipovitch
MZMichael Ziv
Michael Ziv
RDRoni P. Dodiuk-Gad
Roni P. Dodiuk-Gad
(1) Background: Darier disease (DD) is a rare autosomal dominant disorder caused by mutations in ATP2A2, a gene that encodes the sarco(endo)plasmic reticulum calcium-ATPase 2 enzyme, which disrupts calcium homeostasis in keratinocytes. Pruritus, a frequently overlooked symptom in DD, can lead to physical and emotional complications, especially in patients with DD who are genetically predisposed to psychiatric comorbidities. (2) Methods: This study aimed to analyze pruritus and other related symptoms in patients with DD and explore their correlation with neuropsychiatric conditions, psychological challenges, disease severity, and body surface area (BSA) involvement through a retrospective review of a tertiary center. (3) Results: Data from 76 patients (equal gender distribution, mean age 44 years) revealed a prevalence of pruritus of 90.8%, surpassing symptoms such as pain (34.3%) and malodor (43.4%). Burning sensations due to DD lesions were significantly correlated with the diagnosis of comorbid neuropsychiatric conditions (p = 0.047) and psychiatric medication use (p = 0.019). While pruritus correlated with disease severity and %BSA involvement, the findings were not statistically significant. Patients reporting pruritus had a significantly higher Dermatology Life Quality Index symptom score (2.4 ± 1.0), which is defined as the presence of itch, soreness, pain, or stinging, than those who did not (1.5 ± 0.6), indicating accurate symptom reporting. (4) Conclusions: In conclusion, a striking majority of patients with DD experience pruritus, with higher prevalence among those with neuropsychiatric challenges, severe Darier disease, and greater %BSA skin involvement. Clinicians should recognize pruritus as a key therapeutic target and adopt comprehensive treatment approaches that both address the neuropsychiatric comorbidities and the added psychological burden of pruritus in patients with DD.

1 June 2026 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
SLSofia Labbouz
Sofia Labbouz
AHAlain Hovnanian
Alain Hovnanian
GXGrace Xiong
Grace Xiong
DMDedee Frances Murrell
Dedee Frances Murrell
SMSimon Mueller
Simon Mueller
RDRoni Pircha Dodiuk‐Gad
Roni Pircha Dodiuk‐Gad
Darier disease (DD) is a rare autosomal dominant genodermatosis. This comprehensive review, developed by the Darier Disease International Task Force (DDITF), consolidates current knowledge on the genetic basis, molecular pathophysiology, clinical presentation, diagnosis and management of DD, offering a global perspective that unites shared expertise. The disease arises from pathogenic variants in the ATP2A2 gene, which encodes sarco/endoplasmic reticulum Ca 2+ ‐ATPase isoform 2 (SERCA2), leading to disrupted calcium homeostasis and impaired desmosomal integrity. Clinically, DD is classified based on lesion type (classic vs. non‐classic) and is often accompanied by significant extracutaneous manifestations. Management remains challenging and requires a multifaceted approach, including topical therapies, systemic retinoids and lifestyle modifications. Emerging treatments that target the underlying molecular mechanisms offer promise for improved outcomes. This review aims to provide an updated reference and practical guidance for clinicians involved in the care and study of DD.

15 June 2025 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
DRDaniel Rayner
Daniel Rayner
DGDavid Gou
David Gou
JLJennifer Lin
Jennifer Lin
GXGrace Xiong
Grace Xiong
AGAlessandra Giglia
Alessandra Giglia
SBShreya Bera
Shreya Bera

4 September 2025 in Pediatric Dermatology
Verified
Journal Article
Open access
GXGrace Xiong
Grace Xiong
MAMohamed Ali
Mohamed Ali
EKErfan Ghani Kakhki
Erfan Ghani Kakhki
AXAnnie Xiong
Annie Xiong
RARaed Alhusayen
Raed Alhusayen
IMIlya Mukovozov
Ilya Mukovozov
Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent nodules and abscesses in intertriginous areas, ultimately resulting in scarring and formation of sinus tracts. HS significantly impacts quality of life and can also affect pediatric populations. We aimed to determine the prevalence, family history, age of onset, and age at diagnosis of HS in pediatric populations. Methods: A random‐effects meta‐analysis of observational studies was conducted following MOOSE guidelines. Five databases were searched through May 2024. Results: Thirty seven observational studies were included, representing 6941 patients from 13 countries. The weighted mean age was 14.7 years (range: 4–18). Ethnoracial distribution included White (36.5%), Black (38.3%), Hispanic (13.9%), Asian (0.8%), Indigenous (0.2%), Middle Eastern (0.7%), multiracial (1.2%), and unspecified populations (8.4%). Among studies reporting severity, 42.5% had Hurley Stage I, 46.3% Stage II, and 11.2% Stage III. The prevalence of HS in pediatric populations was 0.03% (95% CI [0.0001, 0.0005]), with 38% of patients having a family history of HS (95% CI [0.30, 0.45]). Pediatric‐onset HS predominantly affects females (78%, 95% CI [0.76, 0.80]). The average age of onset of HS in pediatric populations was 11.3 years (95% CI [10.15, 12.39]), but diagnosis typically occurred at 14.0 years (95% CI [12.65, 15.28]), indicating a delay in diagnosis. Female predominance of HS was associated with earlier age of onset and age at diagnosis, while no significant correlations between family history, age of onset, or age at diagnosis were identified. Conclusion: This study highlights the characteristics of pediatric‐onset HS and emphasizes the need for earlier detection to expedite diagnosis and initiation of treatment.